Aerovate Therapeutics Stock Today
| AVTE Stock | USD 22.50 1.12 4.74% |
Performance4 of 100
| Odds Of DistressOver 51
|
Aerovate Therapeutics is trading at 22.50 as of the 18th of April 2024, a -4.74 percent decrease since the beginning of the trading day. The stock's lowest day price was 21.81. Aerovate Therapeutics has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Aerovate Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 2021 | Category Healthcare | Classification Health Care |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. The company has 27.86 M outstanding shares of which 993.09 K shares are presently shorted by private and institutional investors with about 6.04 trading days to cover. More on Aerovate Therapeutics
Moving against Aerovate Stock
| 0.52 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 20th of May 2024
Aerovate Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aerovate Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aerovate Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Aerovate Therapeutics report their recommendations after researching Aerovate Therapeutics' financial statements, talking to executives and customers, or listening in on Aerovate Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Aerovate Therapeutics. The Aerovate consensus assessment is calculated by taking the average forecast from all of the analysts covering Aerovate Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Aerovate Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aerovate Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Aerovate Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Aerovate Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aerovate Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aerovate Therapeutics' financial leverage. It provides some insight into what part of Aerovate Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Aerovate Therapeutics (AVTE) is traded on NASDAQ Exchange in USA. It is located in 930 Winter Street, Waltham, MA, United States, 02451 and employs 51 people. Aerovate Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 658.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aerovate Therapeutics's market, we take the total number of its shares issued and multiply it by Aerovate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Aerovate Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.86 M outstanding shares of which 993.09 K shares are presently shorted by private and institutional investors with about 6.04 trading days to cover.
Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22.
Check Aerovate Therapeutics Probability Of Bankruptcy
Ownership AllocationAerovate Therapeutics retains a total of 27.86 Million outstanding shares. The majority of Aerovate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aerovate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aerovate Therapeutics. Please pay attention to any change in the institutional holdings of Aerovate Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Aerovate Ownership Details
Aerovate Stock Price Odds Analysis
What are Aerovate Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Aerovate Therapeutics jumping above the current price in 90 days from now is about 55.3%. The Aerovate Therapeutics probability density function shows the probability of Aerovate Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.5275. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Aerovate Therapeutics will likely underperform. Additionally, aerovate Therapeutics has an alpha of 0.1989, implying that it can generate a 0.2 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Aerovate Therapeutics to move above the current price in 90 days from now is about 55.3 (This Aerovate Therapeutics probability density function shows the probability of Aerovate Stock to fall within a particular range of prices over 90 days) .
Aerovate Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Aerovate Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aerovate Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aerovate Therapeutics' value.| Instituion | Recorded On | Shares | |
| Fmr Inc | 2023-12-31 | 537.5 K | |
| Octagon Capital Advisors Lp | 2023-09-30 | 497.4 K | |
| Vestal Point Capital Lp | 2023-12-31 | 400 K | |
| Geode Capital Management, Llc | 2023-12-31 | 276.9 K | |
| State Street Corporation | 2023-12-31 | 214 K | |
| Ghost Tree Capital, Llc | 2023-12-31 | 210 K | |
| Nantahala Capital Management, Llc | 2023-12-31 | 182.4 K | |
| Paradigm Biocapital Advisors Lp | 2023-12-31 | 143.2 K | |
| Ensign Peak Advisors Inc | 2023-12-31 | 122.3 K | |
| Ra Capital Management, Llc | 2023-12-31 | 8.3 M | |
| Sofinnova Ventures | 2023-12-31 | 3.8 M |
Aerovate Therapeutics Historical Income Statement
Aerovate Therapeutics Income Statement is one of the three primary financial statements used for reporting Aerovate's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Aerovate Therapeutics revenue and expense. Aerovate Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Aerovate Therapeutics' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 85.5 M, whereas Selling General Administrative is forecasted to decline to about 9 M. View More FundamentalsAerovate Stock Against Markets
Picking the right benchmark for Aerovate Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aerovate Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aerovate Therapeutics is critical whether you are bullish or bearish towards Aerovate Therapeutics at a given time. Please also check how Aerovate Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Aerovate Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Aerovate Therapeutics Corporate Management
Elected by the shareholders, the Aerovate Therapeutics' board of directors comprises two types of representatives: Aerovate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aerovate. The board's role is to monitor Aerovate Therapeutics' management team and ensure that shareholders' interests are well served. Aerovate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aerovate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Pigot | VP Commercial | Profile | |
| Benjamin Dake | President, Founder | Profile | |
| Timothy MBA | CEO Director | Profile | |
| Marinus Verwijs | Chief Officer | Profile | |
| Stephen Yu | Senior Quality | Profile | |
| BSc MD | Senior Development | Profile | |
| Hunter MD | Chief Officer | Profile |
How to buy Aerovate Stock?
Before investing in Aerovate Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Aerovate Therapeutics. To buy Aerovate Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Aerovate Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Aerovate Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Aerovate Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Aerovate Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Aerovate Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Aerovate Stock please use our How to Invest in Aerovate Therapeutics guide.
Already Invested in Aerovate Therapeutics?
The danger of trading Aerovate Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aerovate Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aerovate Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aerovate Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Aerovate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.39) | Return On Equity (0.64) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.